歌礼制药-B(01672)完成配售6925.6万股股份 净筹约8.35亿港元

Core Viewpoint - Company completed the placement of a total of 69.256 million shares at a price of HKD 12.18 per share, raising approximately HKD 835 million, with 90% allocated for the global Phase III clinical trial preparation of the obesity treatment small molecule oral GLP-1 receptor agonist ASC30 [1] Group 1 - The placement was completed on February 10, 2026 [1] - Approximately 90% of the raised funds will be used for the preparation, groundwork, and initiation of the global Phase III clinical trial for ASC30 [1] - The remaining 10% of the funds is suggested for operational expenses and other general corporate purposes [1]